Literature DB >> 23376392

Is bridging with intravenous thrombolysis of any benefit in endovascular therapy for acute ischemic stroke?

Tareq Kass-Hout1, Omar Kass-Hout1, Maxim Mokin2, Danielle M Thesier3, Parham Yashar4, David Orion2, Shady Jahshan2, L Nelson Hopkins5, Adnan H Siddiqui5, Kenneth V Snyder6, Elad I Levy7.   

Abstract

OBJECTIVE: Large vessel occlusions with heavy clot burden are less likely to improve with intravenous (IV) thrombolysis alone. The purpose of this study was to show whether a combination of IV thrombolysis and endovascular therapy was superior to endovascular treatment alone.
METHODS: Data for 104 patients with acute large artery occlusion treated between 2005 and 2010 were reviewed. Forty-two received endovascular therapy in combination with IV thrombolysis (bridging group), and 62 received endovascular therapy only. Clinical outcome, mortality rate, and symptomatic intracranial hemorrhage (sICH) rate were compared between the two groups.
RESULTS: The two groups had similar demographic and vascular risk factor distribution, as well as National Institutes of Health Stroke Scale score on admission (mean±SD: 14.8±4.7 and 16.0±5.3; P=0.23). No difference was found in Thrombolysis in Myocardial Infarction recanalization rates (score of 2 or 3) after combined or endovascular therapy alone (83.33% and 79.03%; P=0.585). Favorable outcome, defined as a modified Rankin Scale score of <2 at 90 days, also did not differ between the bridging group and the endovascular-only group (37.5% and 32.76%; P=0.643). There was no difference in mortality rate (19.04% and 29.03%; P=0.5618) and sICH rate (11.9% and 9.68%; P=0.734). A significant difference was found in mean time from symptom onset to treatment in the bridging group and the endovascular-only group (227±88 min vs. 125±40 min; P<0.0001).
CONCLUSION: Combining IV thrombolysis with endovascular therapy resulted in similar outcome, revascularization, sICH, and mortality rates compared with endovascular therapy alone. Prospective clinical studies comparing both treatment strategies in acute ischemic stroke are warranted.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute ischemic stroke; Bridging; Intra-arterial therapy; Tissue plasminogen activator

Mesh:

Substances:

Year:  2013        PMID: 23376392     DOI: 10.1016/j.wneu.2013.01.097

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  16 in total

1.  Short and long-term outcomes after combined intravenous thrombolysis and mechanical thrombectomy versus direct mechanical thrombectomy: a prospective single-center study.

Authors:  Giovanni Merlino; Massimo Sponza; Benedetto Petralia; Alessandro Vit; Vladimir Gavrilovic; Andrea Pellegrin; Michele Rana; Iacopo Cancelli; Sara Naliato; Simone Lorenzut; Roberto Marinig; Ferdinando Calzolari; Roberto Eleopra
Journal:  J Thromb Thrombolysis       Date:  2017-08       Impact factor: 2.300

2.  Endovascular thrombectomy with or without systemic thrombolysis?

Authors:  Georgios Tsivgoulis; Aristeidis H Katsanos; Dimitris Mavridis; Anne W Alexandrov; Georgios Magoufis; Adam Arthur; Valeria Caso; Peter D Schellinger; Andrei V Alexandrov
Journal:  Ther Adv Neurol Disord       Date:  2016-12-01       Impact factor: 6.570

3.  Reperfusion of very low cerebral blood volume lesion predicts parenchymal hematoma after endovascular therapy.

Authors:  Nishant K Mishra; Søren Christensen; Anke Wouters; Bruce C V Campbell; Matus Straka; Michael Mlynash; Stephanie Kemp; Carlo W Cereda; Roland Bammer; Michael P Marks; Gregory W Albers; Maarten G Lansberg
Journal:  Stroke       Date:  2015-03-31       Impact factor: 7.914

Review 4.  Outcomes of mechanical thrombectomy with pre-intravenous thrombolysis: a systematic review and meta-analysis.

Authors:  Lu Fan; Lin Zang; Xiaodong Liu; Jian Wang; Jianting Qiu; Yujie Wang
Journal:  J Neurol       Date:  2020-03-05       Impact factor: 4.849

Review 5.  Intravenous thrombolysis before mechanical thrombectomy for acute ischemic stroke due to large vessel occlusion; should we cross that bridge? A systematic review and meta-analysis of 36,123 patients.

Authors:  Hazem S Ghaith; Mohamed Elfil; Mohamed Diaa Gabra; Asmaa Ahmed Nawar; Mohamed Sameh Abd-Alkhaleq; Khaled M Hamam; Lara Ebrahim Aboelnasr; Esraa Ayman Elgezery; Mohamed Hosny Osman; Hanaa Elsayed; Sarya Swed; Ulrick Sidney Kanmounye; Ahmed Negida
Journal:  Neurol Sci       Date:  2022-07-23       Impact factor: 3.830

6.  Bridging Therapy with i. v. rtPA in MCA Occlusion Prior to Endovascular Thrombectomy: a Double-Edged Sword?

Authors:  Johannes Kaesmacher; Justus F Kleine
Journal:  Clin Neuroradiol       Date:  2016-08-19       Impact factor: 3.649

7.  Intravenous r-tPA Dose Influence on Outcome after Middle Cerebral Artery Ischemic Stroke Treatment by Mechanical Thrombectomy.

Authors:  Marius Kurminas; Andrius Berūkštis; Nerijus Misonis; Karmela Blank; Algirdas Edvardas Tamošiūnas; Dalius Jatužis
Journal:  Medicina (Kaunas)       Date:  2020-07-17       Impact factor: 2.430

8.  Inhouse Bridging Thrombolysis Is Associated With Improved Functional Outcome in Patients With Large Vessel Occlusion Stroke: Findings From the German Stroke Registry.

Authors:  Ilko L Maier; Andreas Leha; Mostafa Badr; Ibrahim Allam; Mathias Bähr; Ala Jamous; Amelie Hesse; Marios-Nikos Psychogios; Daniel Behme; Jan Liman
Journal:  Front Neurol       Date:  2021-06-10       Impact factor: 4.003

Review 9.  Reperfusion therapy in acute ischemic stroke: dawn of a new era?

Authors:  Sonu Bhaskar; Peter Stanwell; Dennis Cordato; John Attia; Christopher Levi
Journal:  BMC Neurol       Date:  2018-01-16       Impact factor: 2.474

10.  Direct versus Bridging Mechanical Thrombectomy in Elderly Patients with Acute Large Vessel Occlusion: A Multicenter Cohort Study.

Authors:  Yating Jian; Lili Zhao; Baixue Jia; Xu Tong; Tao Li; Yulun Wu; Xiaoya Wang; Zhen Gao; Yu Gong; Xuelei Zhang; Huqing Wang; Ru Zhang; Lei Zhang; Zhongrong Miao; Guilian Zhang
Journal:  Clin Interv Aging       Date:  2021-07-05       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.